{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:34:28Z","timestamp":1787164468527,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020703","name":"Department of Pharmaceutical Sciences, St. John&apos;s University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010937","name":"St. John&apos;s University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.yexcr.2025.114851","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T01:32:40Z","timestamp":1765416760000},"page":"114851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Overcoming multidrug resistance in cancer cells targeting ABC transporter ABCB1 with tyrosine kinase inhibitor: Olverembatinib"],"prefix":"10.1016","volume":"455","author":[{"given":"Bohan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4005-9549","authenticated-orcid":false,"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingduo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6884-8890","authenticated-orcid":false,"given":"Yidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-3293","authenticated-orcid":false,"given":"Letao","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-8931","authenticated-orcid":false,"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.yexcr.2025.114851_bib1","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.7150\/thno.57828","article-title":"Recent progress in nanomedicine for enhanced cancer chemotherapy","volume":"11","author":"Wei","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.yexcr.2025.114851_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.yexcr.2025.114851_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2021.05.012","article-title":"The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy","volume":"335","author":"Liu","year":"2021","journal-title":"J. Contr. Release"},{"issue":"7","key":"10.1016\/j.yexcr.2025.114851_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15071963","article-title":"The battlefield of chemotherapy in pediatric cancers","volume":"15","author":"Bo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.yexcr.2025.114851_bib5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","article-title":"Understanding and overcoming multidrug resistance in cancer","volume":"22","author":"Ge","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114851_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/mr-2023-0058","article-title":"Nanotechnology-based delivery systems to overcome drug resistance in cancer","volume":"4","author":"Patel","year":"2021","journal-title":"Mediev. Rev."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114851_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103537","article-title":"ATP-Binding cassette efflux transporters and MDR in cancer","volume":"28","author":"Pote","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114851_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40880-017-0219-2","article-title":"Autophagy and multidrug resistance in cancer","volume":"36","author":"Li","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.yexcr.2025.114851_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","article-title":"The DNA damage response: implications for tumor responses to radiation and chemotherapy","volume":"66","author":"Goldstein","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"9","key":"10.1016\/j.yexcr.2025.114851_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2025.114851_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/978-981-13-7647-4_12","article-title":"ABC transporter-mediated multidrug-resistant cancer","volume":"1141","author":"Amawi","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.yexcr.2025.114851_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108488","article-title":"Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review","volume":"249","author":"Dong","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yexcr.2025.114851_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101065","article-title":"ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C","volume":"73","author":"Lei","year":"2024","journal-title":"Drug Resist. Updates"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114851_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/fcp.12505","article-title":"NRF2\/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells","volume":"34","author":"Xia","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114851_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-023-02879-8","article-title":"ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells","volume":"43","author":"Bergonzini","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.yexcr.2025.114851_bib16","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.2174\/1568026617666170104143618","article-title":"Novel colchicine derivatives and their anti-cancer activity","volume":"17","author":"Johnson","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114851_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00280-023-04580-1","article-title":"Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy","volume":"92","author":"Nakagawa","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.yexcr.2025.114851_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217309","article-title":"Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies","volume":"607","author":"Dong","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexcr.2025.114851_bib19","doi-asserted-by":"crossref","DOI":"10.2174\/0115748928357067250512112852","article-title":"B-9-8, a Novel Harman Dimer, Reverses ABCG2-mediated Chemotherapeutic Drug Resistance","author":"Zhao","year":"2025","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114851_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/10717544.2021.1905751","article-title":"Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance","volume":"28","author":"Zhang","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.yexcr.2025.114851_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fonc.2019.00313","article-title":"Glesatinib, a c-MET\/SMO dual inhibitor, antagonizes P-glycoprotein mediated multidrug resistance in cancer cells","volume":"9","author":"Cui","year":"2019","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.yexcr.2025.114851_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/1061186X.2018.1497039","article-title":"Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an in-vitro, in-vivo and mechanistic investigation","volume":"27","author":"Negi","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.yexcr.2025.114851_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","article-title":"Acquired resistance to drugs targeting tyrosine kinases","volume":"138","author":"Rosenzweig","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114851_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fcell.2020.00865","article-title":"Bruton's tyrosine kinase (BTK) inhibitor RN486 overcomes ABCB1-Mediated multidrug resistance in cancer cells","volume":"8","author":"Dong","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114851_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114851_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.yexcr.2025.114851_bib27","first-page":"2961","article-title":"Isolation of human KB cell lines resistant to epidermal growth factor-Pseudomonas exotoxin conjugates","volume":"47","author":"Lyall","year":"1987","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114851_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/ijc.2910490512","article-title":"P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human Colon carcinoma cell lines","volume":"49","author":"Lai","year":"1991","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2025.114851_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.yexcr.2025.114851_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.yexcr.2025.114851_bib31","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20204092","article-title":"Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers","volume":"41","author":"Abd El-Aziz","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.yexcr.2025.114851_bib32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.34133\/research.0911","article-title":"tRF3a-MetCAT promotes EGFR-Targeted therapeutic resistance through the TRIM21-STAT1-C5a axis in lung adenocarcinoma","volume":"8","author":"Zhang","year":"2025","journal-title":"Research"},{"key":"10.1016\/j.yexcr.2025.114851_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2015.11.019","article-title":"Novel in vitro transport method for screening the reversibility of P-glycoprotein inhibitors","volume":"100","author":"Netsomboon","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.yexcr.2025.114851_bib34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clml.2023.04.012","article-title":"Olverembatinib treatment in pediatric patients with relapsed philadelphia-chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.yexcr.2025.114851_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1036437","article-title":"A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.yexcr.2025.114851_bib36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00277-023-05519-5","article-title":"Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report","volume":"103","author":"Fan","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.yexcr.2025.114851_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1065130","article-title":"Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725004513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725004513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:41:12Z","timestamp":1773902472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482725004513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0014482725004513"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114851","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming multidrug resistance in cancer cells targeting ABC transporter ABCB1 with tyrosine kinase inhibitor: Olverembatinib","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114851"}}